socalTECH

MARCH 15, 2012

San Diego-based Avalon Ventures , one of the venture capital investors in social gaming phenomenon Zynga , may be set to cash in on its shares of the newly public gaming firm, after Zynga said this week that it is planning a $400M, secondary offering of its stock.

Avalon 150

Avalon Southern California SoCal San Diego 150

socalTECH

JULY 1, 2011

According to Zynga, it is looking to raise up to $1 billion on the public markets. Among the investors who may benefit from a successful IPO are La Jolla-based Avalon Ventures , run by Kevin Kinsella, Stephen Tomlin, Richard Levandov, Brady Bohrmann, Doug Downs and Jay Lichter, which before the IPO owned 6.1 percent of Zynga.

Avalon 140

Avalon Southern California Class Marketing 140

socalTECH

JUNE 11, 2021

The company begins trading this morning on the Nasdaq Global market under the ticker symbol JANX. The company's biggest shareholders before the IPO were Avalon Ventures, RA Capital Healthcare, Orbimed, Bregua Corporation, and Correlation Ventures. Janux Therapeutics is developing T cell engager immunotherapies.

Pricing 113

Pricing Avalon Capital Marketing 113

socalTECH

FEBRUARY 5, 2014

The company is offering up 3,529,411 shares of its stock, and plans to trade on the NASDAQ Global Market as INGN. Inogen is venture backed by Novo AS, Versant Ventures, Arborteum Ventures, Avalon Ventures, and Accuitive Medical Ventures. inogen merger acquisition exist medical equipment lifescience ingn' READ MORE>>.

Avalon 214

Avalon Pricing Acquisition Marketing 214

socalTECH

JULY 14, 2014

San Diego-based Otonomy , the biopharmaceuticals firm which is developing treatment of diseases and disorders of the ear, has filed for an IPO, saying in a filing that it is looking to raised $86.25M in an offering on the NASDAQ Global Market. otonomy biopharmaceuticals biotech lifescience merger acquisition inner disease exit'

Avalon 147

Avalon San Diego Acquisition Marketing 147

socalTECH

JANUARY 17, 2017

The company is selling 4,000,000 shares of its common stock on the NASDAQ Global Select Market as ANAB. AnaptysBio is backed by Frazier Healthcare, Novo A/S, Avalon Ventures, Alloy Ventures, Biotechnology Value Fund, HBM Healthcare Investments, and others. as early as Thursday.

Pricing 100

Pricing Avalon Southern California Venice 100

socalTECH

AUGUST 13, 2014

today after its debut on the NASDAQ Global Market as OTIC. Otonomy was backed by Avalon Ventures, OrbiMed, Novo A/S, TPG Biotechnology Partners, Domain Associates, and Rivervest Venture Partners. Otonomy was backed by Avalon Ventures, OrbiMed, Novo A/S, TPG Biotechnology Partners, Domain Associates, and Rivervest Venture Partners.

Avalon 138

Avalon San Diego Pricing Acquisition 138